- Home
- RVPH vs CUE Comparison
RVPH vs CUE Comparison
Compare RVPH & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- CUE
- Stock Information
- Founded
- RVPH 2006
- CUE 2014
- Country
- RVPH United States
- CUE United States
- Employees
- RVPH N/A
- CUE N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- CUE Health Care
- Exchange
- RVPH Nasdaq
- CUE Nasdaq
- Market Cap
- RVPH 32.8M
- CUE 48.0M
- IPO Year
- RVPH N/A
- CUE 2018
- Fundamental
- Price
- RVPH $0.40
- CUE $0.74
- Analyst Decision
- RVPH Strong Buy
- CUE Strong Buy
- Analyst Count
- RVPH 5
- CUE 3
- Target Price
- RVPH $9.00
- CUE $3.00
- AVG Volume (30 Days)
- RVPH 3.4M
- CUE 323.3K
- Earning Date
- RVPH 08-13-2025
- CUE 08-13-2025
- Dividend Yield
- RVPH N/A
- CUE N/A
- EPS Growth
- RVPH N/A
- CUE N/A
- EPS
- RVPH N/A
- CUE N/A
- Revenue
- RVPH N/A
- CUE $7,991,000.00
- Revenue This Year
- RVPH N/A
- CUE N/A
- Revenue Next Year
- RVPH N/A
- CUE $23.84
- P/E Ratio
- RVPH N/A
- CUE N/A
- Revenue Growth
- RVPH N/A
- CUE 13.83
- 52 Week Low
- RVPH $0.30
- CUE $0.45
- 52 Week High
- RVPH $4.28
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- RVPH 33.44
- CUE 51.10
- Support Level
- RVPH $0.35
- CUE $0.65
- Resistance Level
- RVPH $0.83
- CUE $0.83
- Average True Range (ATR)
- RVPH 0.06
- CUE 0.07
- MACD
- RVPH -0.01
- CUE 0.01
- Stochastic Oscillator
- RVPH 17.36
- CUE 30.43
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.